⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VOR News
Vor Biopharma Inc. Common Stock
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
globenewswire.com
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VOR
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
globenewswire.com
VOR
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight
globenewswire.com
NVS
ALLO
LEGN
CBIO
MBIO
CRSP
INCY
IMPP
SANA
VOR
CARG
AUTL
ARCL
LYEL
PRE
BEAM
CART
TAK
AZN
MRK
BMY
GEN
DGX
GMAB
ABBV
RLGT
CRGO
JNJ
GILD
JAZZ
SYBX
CASI
ATRA
SHEN
BIIB
VREX
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
globenewswire.com
VOR
$5.29 Billion Genome Editing Market Analysis and Leading Industry Players, 2026: Trends and Growth Forecast to 2035
globenewswire.com
ARCT
BTAI
CRSP
EDIT
NTLA
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VOR
Vor Bio To Participate in Upcoming September Conferences
globenewswire.com
VOR
VORAGO Climbs 2026 Inc. 5000 List for 5th Year, Driving Growth in Extreme Radiation- and Thermal-Protected Satellite and Space Chips
businesswire.com
VOR
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
VOR